NEW YORK (GenomeWeb) — Cancer Genetics reported after the close of the market Monday a 26 percent drop in its third quarter revenues due to declines across its biopharma, clinical, and discovery services units.

For the three-month period ended Sept. 30, Rutherford, New Jersey-based CGI posted revenues of $5.9 million versus $8.0 million in the same period a year before.